Investigating gene therapy to treat atrial fibrillation
Calcium and MAPKinase Signaling and Structural Remodeling in Atrial Fibrillation
['FUNDING_R01'] · UNIV OF MASSACHUSETTS MED SCH WORCESTER · NIH-10824235
This study is exploring a new gene therapy to help people with atrial fibrillation by fixing the heart's electrical and structural problems, with the hope of improving heart function and reducing symptoms.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MASSACHUSETTS MED SCH WORCESTER (nih funded) |
| Locations | 1 site (WORCESTER, UNITED STATES) |
| Trial ID | NIH-10824235 on ClinicalTrials.gov |
What this research studies
This research focuses on atrial fibrillation (AF), a common heart rhythm disorder that can lead to serious health issues. The team aims to develop gene therapy as a new treatment approach by targeting the underlying mechanisms of AF, specifically electrical and structural remodeling in the heart. By using gene transfer techniques, they hope to reverse the changes that contribute to AF, potentially improving heart function and reducing symptoms. The research involves advanced methodologies to assess the effectiveness of these gene therapies in restoring normal heart rhythm.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with atrial fibrillation who have not responded well to existing treatments.
Not a fit: Patients with atrial fibrillation who are already effectively managed with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel gene therapy that effectively treats atrial fibrillation, improving patient outcomes and quality of life.
How similar studies have performed: While gene therapy for atrial fibrillation is a relatively novel approach, there have been successful applications of gene therapy in other cardiovascular conditions, suggesting potential for success in this area.
Where this research is happening
WORCESTER, UNITED STATES
- UNIV OF MASSACHUSETTS MED SCH WORCESTER — WORCESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DONAHUE, J KEVIN — UNIV OF MASSACHUSETTS MED SCH WORCESTER
- Study coordinator: DONAHUE, J KEVIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.